9:34 AM
 | 
Mar 16, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the 18,924-patient Phase III ODYSSEY OUTCOMES trial showing that Praluent alirocumab given on top of statins lowered the risk of major adverse cardiovascular events (MACE) by 15% (HR=0.85, CI: 0.78, 0.93, p=0.0003). The MACE composite endpoint includes patients who experienced a heart attack, stroke, death from coronary heart disease (CHD) or unstable angina requiring hospitalization. Data were presented at the American College of Cardiology meeting in Orlando.

Armed with the cardiovascular outcomes data and a fresh cost-effectiveness analysis from the Institute for Clinical and Economic Review (ICER), the partners also proposed to reduce barriers to access in high-risk patients, offering up to a 69% discount to the PCSK9 inhibitor’s list price.

“We commit to working with all health plans that agree to remove access barriers for high-risk patients to offer a more cost-effective net price for Praluent,” said Regeneron President and CEO Leonard Schleifer in a statement issued March 10 following the results of ODYSSEY OUTCOMES.

Praluent was also associated with a lower risk of all-cause mortality (HR=0.85, CI: 0.73, 0.98, p=0.026). In a pre-specified analysis, the patients with baseline LDL-C levels at or above 100 mg/dL had a 24% reduction in the risk of MACE...

Read the full 1012 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >